Heterocyclic derivatives for the treatment of RSV

1. A compound of Formula 1b-1:

or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof, wherein

z is 0;

y is 1;

R 1 and R 2 are independently selected from the group consisting of R a , OR a ′, N(R a ) 2 , SR a , C(═O)R a , C(═O)OR a ′, C(═O)N(R a ) 2 , and C(═O)SR a ;

wherein two or more R 1 , R 2 , or R a groups may independently form a ring;

wherein R a is selected from the group consisting of hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 heterocyclyl, C 6-12 aryl, C 3-12 heteroaryl, C 1-8 alkyl-C 3-8 cycloalkyl, C 1-8 alkyl-C 2-8 heterocyclyl, C 1-8 alkyl-C 6-12 aryl, and C 1-8 alkyl-C 3-12 heteroaryl;

wherein a is 1, 2, 3 or 4; and R 8 is selected from the group consisting of —OR a ′, —N(R a ) 2 , —SR a , —SO 2 R a , —SO 2 N(R a ) 2 ; —C(O)R a , OC(O)R a , —COOR a , —C(O)N(R a ) 2 , —OC(O)N(R a ) 2 , —N(R a )C(O), —N(R a )C(O)N(R a ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 ; and

wherein R 1 is not NH—CH2-CH2-phenyl.

2. The compound according to claim 1 wherein the compound is selected from the group consisting of:

3. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, vehicle, or excipient.

4. The pharmaceutical composition according to claim 3 wherein the compound is selected from the group consisting of:

5. The pharmaceutical composition according to claim 4 wherein the compound is selected from the group consisting of:

6. The compound according to claim 1 , wherein R 1 is selected from the group consisting of:

b is 0, 1, 2, 3, or 4,

R 9 is selected from the group consisting of —R a , —OR a ′, —N(R a ) 2 , —SR a , —SO 2 R a , —SO 2 N(R a ) 2 ; —C(O)R a , OC(O)R a , —COOR a , —C(O)N(R a ) 2 , —OC(O)N(R a ) 2 , —N(R a )C(O), —N(R a )C(O)N(R a ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 , wherein any two or more R 9 groups may together form a ring;

wherein R 10 is selected from the group consisting of R a , C(O)R a , SO 2 R a , COOR a , and C(O)N(R a ) 2 , and wherein R 10 may form a ring with any R 1 , R 2 , R 8 , or R a groups.

7. A method of inhibiting RSV comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

8. The method according to claim 7 , wherein R 1 is selected from the group consisting of:

b is 0, 1, 2, 3, or 4,

R 9 is selected from the group consisting of —R a , —OR a ′, —N(R a ) 2 , —SR a , —SO 2 R a , —SO 2 N(R a ) 2 ; —C(O)R a , OC(O)R a , —COOR a , —C(O)N(R a ) 2 , —OC(O)N(R a ) 2 , —N(R a )C(O), —N(R a )C(O)N(R a ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 , wherein any two or more R 9 groups may together form a ring;

wherein R 10 is selected from the group consisting of R a , C(O)R a , SO 2 R a , COOR a , and C(O)N(R a ) 2 , and wherein R 10 may form a ring with any R 1 , R 2 , R 8 , or R a groups.

9. The method according to claim 7 , wherein R 1 is a group of the formula:

10. The method according to claim 7 , wherein R 2 is C(═O)NHR a1 , wherein said R a1 is selected from the group consisting of C 3-8 cycloalkyl, C 2-8 heterocyclyl, C 6-12 aryl, and C 3-12 heteroaryl.

11. The method according to claim 7 , wherein R 2 is C(═O)NH—C 3-8 cycloalkyl.

12. The method according to claim 7 , wherein R 2 is C(═O)NHcyclohexyl.

13. The method according to claim 7 wherein the compound is selected from the group consisting of:

14. A method of treating an RSV infection, comprising administering to a patient in need thereof, an effective amount of the compound of claim 1 .

15. The method of treating an RSV infection according to claim 14 wherein the compound is administered via a route of administration selected from the group consisting of buccal, oral, intravenous, inhalation, intradermal, intramuscular, topical, subcutaneous, rectal, vaginal, parenteral, pulmonary, intranasal, and ophthalmic.

16. The method of treating an RSV infection according to claim 14 wherein the compound is selected from the group consisting of: